7 results
10-K
2021 FY
ACXP
Acurx Pharmaceuticals, Inc.
16 Mar 22
Annual report
4:05pm
subtilis (Ki 0.34 µM) in in vitro resting. C. difficile has a single circular chromosome and one origin of replication (oriC) from which DNA
424B4
ACXP
Acurx Pharmaceuticals, Inc.
28 Jun 21
Prospectus supplement with pricing info
6:02am
Bacillus subtilis (Ki 0.34 µM) in in vitro resting. C. difficile has a single circular chromosome and one origin of replication (oriC) from which DNA
S-1/A
ACXP
Acurx Pharmaceuticals, Inc.
11 Jun 21
IPO registration (amended)
6:02am
IIIC derived from C. difficile (Ki 0.325 µM) and from Bacillus subtilis (Ki 0.34 µM) in in vitro resting. C. difficile has a single circular
S-1
ACXP
Acurx Pharmaceuticals, Inc.
27 May 21
IPO registration
12:00am
from C. difficile (Ki 0.325 µM) and from Bacillus subtilis (Ki 0.34 µM) in in vitro resting. C. difficile has a single circular chromosome and one
DRS/A
sh2c6n9i qj7ch
10 May 21
Draft registration statement (amended)
12:00am
DRS
543hj963d2oavh
5 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next